S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

$43.50
-0.14 (-0.32%)
(As of 04/16/2024 ET)
Today's Range
$43.14
$43.87
50-Day Range
$43.64
$63.86
52-Week Range
$18.43
$64.98
Volume
284,704 shs
Average Volume
470,803 shs
Market Capitalization
$2.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.46

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
71.2% Upside
$74.46 Price Target
Short Interest
Bearish
16.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$9.49 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.11) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

584th out of 930 stocks

Pharmaceutical Preparations Industry

266th out of 418 stocks

MLTX stock logo

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

MLTX Stock News Headlines

BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
BUY ALERT: Billionaires piling into this asset class
Legendary investor Warren Buffett has poured over $500 million into gold! It's a BIG move by one of the world's most cautious investors.
MLTX Aug 2024 80.000 call
MLTX May 2024 60.000 call
MLTX Apr 2024 40.000 put
MoonLake Stock (NASDAQ:MLTX), Short Interest Report
MLTX Mar 2024 80.000 call
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/16/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$74.46
High Stock Price Target
$100.00
Low Stock Price Target
$56.00
Potential Upside/Downside
+71.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-36,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.15 per share

Miscellaneous

Free Float
54,131,000
Market Cap
$2.78 billion
Optionable
Optionable
Beta
1.20
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price target for 2024?

12 brokerages have issued 12-month price objectives for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $100.00. On average, they anticipate the company's stock price to reach $74.46 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX stock has decreased by 28.0% and is now trading at $43.50.
View the best growth stocks for 2024 here
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.11.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners